Bioversys

Public

Basel, Basel-StadtBiotechhttps://www.bioversys.com

Bioversys is now publicly traded

The data on this page reflects Bioversys's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Feb 7, 2025

Last Round

Strategic

Sep 11, 2024

Total Funding Raised

$210.09M

Company Overview

Bioversys operates in Biotech and is based in Basel, Basel-Stadt. Its recorded funding history includes a Strategic round in September 2024.

BioVersys is a biotechnology company specializing in the research and development of small molecules targeting novel bacterial infections to provide new treatment options for life-threatening antibiotic-resistant conditions.

Sector

Biotech

AI Layer

Non-AI

Bioversys Comparables

Compare Bioversys with similar companies based on industry and business-model similarity.

Bioversys comparables — related companies by embedding similarity
Company	Similarity	Market Cap
VenatoRx Pharmaceuticals	76%	Demo
ARIVA Med GmbH	71%	Demo
Trellis Bioscience	70%	Demo

Book a demo to see all comparables

For institutional investors. Book with your work email.

Bioversys Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
IPO	Feb 7, 2025	Demo	Demo	Demo	Demo
Strategic	Sep 11, 2024	Demo	Demo	Demo	Demo
Series C Extension	May 7, 2024	Demo	Demo	Demo	Demo
Series C Extension	Jan 5, 2023	Demo	Demo	Demo	Demo
Series C	Jun 8, 2022	Demo	Demo	Demo	Demo
Grant	Jun 1, 2021	Demo	Demo	Demo	Demo

Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Bioversys Investors

Notable investors and investment history

Bioversys investors
Investor	Rounds
AMR Action Fund	Series C Extension, IPO, Series C
CR Ventures	Series C
EVA – the Basel life sciences start-up agency	Seed
CARB-X	Grant
Bundesministerium für Bildung und Forschung	Grant
Innovative Health Initiative	Grant
Citigroup Global Markets Limited	IPO